Retina

Durga Borkar, MD, sat down with Sydney Crago of Modern Retina to discuss one of her presentations on the 12-month outcomes of the FARETINA and FARWIDE studies from the Retina Society meeting being held this year in Lisbon, Portugal.

CHG is an effective alternative antiseptic to PI and the cost is outweighed by increased patient comfort.

In a presentation at the Retina Society meeting in Lisbon, Portugal, Ivana Kim, MD, explained that AU-011 (Bel-Sar) demonstrated 80% tumor control rate, 90% visual acuity preservation, and a favorable safety profile.

Jennifer Lim, MD, FARVO, FASRS, discusses her presentation on differential artery-vein analysis and how it improves OCTA performance for AI classification of diabetic retinopathy at the annual Retina Society meeting being held this year in Lisbon, Portugal.

Aflibercept biosimilars have cleared several hurdles on their way to marketplace

Lynn Hassman, MD, PhD, has received the Philip and Elaine Ellis New Investigator in Ophthalmology Research Award, and will focus on seeking treatment options for uveitis patients.

The Retina Society meeting will take place in Lisbon, Portugal from September 11-15, 2024.

Identifying all genetic culprits may improve diagnostics and prognoses.

The one-time intravitreally delivered gene therapy is for the treatment of retinitis pigmentosa (RP).

A team of researchers at the Center for Regenerative Therapies Dresden of Dresden University of Technology is working to develop a method to replace or regenerate damaged photoreceptor cells in the human retina.

The product candidate is a modifier gene therapy for broad retinitis pigmentosa indication.

The option is a definitive step forward in the field of vitreoretinal surgery

According to the company, the priority review voucher would be issued upon approval of OPGx-LCA5.

The growing body of evidence that suggests that maintaining adequate levels of vitamin D may be beneficial for preventing and managing RVO.

Stephen R. Russell, MD, discussed the 9-year data he presented at the American Society of Retina Specialists annual meeting for voretigene neparvovec-rzyl.

Technologies continue to push retina surgical suites into the future

According to the company, the priority review voucher would be issued upon approval of ATSN-201, a gene therapy product candidate.

Researchers noted that patients with sickle cell disease had an increased risk of developing any retinal vascular occlusion.

Researchers conducted a retrospective cohort study that included adult patients 18 years and older who underwent primary repair of uncomplicated rhegmatogenous retinal detachment at the Wilmer Eye Institute from January 2008 to December 2018.

Michael Abramoff, MD, PhD, a retina specialist and founder and executive chairman of Digital Diagnostics, points out that much evidence has been collected over the past few decades showing that early detection is key.

The program is for candidate OCU400, a modifier gene therapy product candidate.

The company hosted a virtual KOL event focusing on applicability and real-world experience with suprachoroidal drug delivery, the SCS as a differentiator in the retinal treatment landscape with a focus on wet AMD, and ongoing SCS clinical programs.

According to the company, the wearable smart glasses with both vision enhancement and assistance will be introduced at the American Retina Forum National Meeting

The service expands ophthalmological capabilities and enables providers to deliver the gift of sight to patients with complex retinal conditions in Harlem.

According to the researchers, the findings suggest drusen formation is a downstream effect of AKT2-related lysosome dysfunction and points to a new target for therapeutic intervention.

In a study, a team of researchers with the OhioHealth Grant Medical Center Family Medicine practice implemented diabetic retinopathy screening using in-clinic retinal photographs and automated software analysis to increase screening rates.

According to the company, VCN-01, its lead product candidate, is a systemic, selective, stroma-degrading oncolytic adenovirus. The FDA had previously granted orphan drug designation to VCN-01 for treatment of retinoblastoma.

KIO-30 is a small molecule photoswitch that selectively confers light-sensing capabilities to retinal ganglion cells following the degeneration of photoreceptors in inherited retinal diseases.